Patients with stage IV or unresectable not irradiable stage III NSCLC will be registered at the time receiving immunotherapy alone or in combination with chemotherapy.~When IO is stopped, reason for cessation and further treatment will be recorded.~Secondary endpoints are survival after IO cessation, activity of first salvage therapy, disease-free survival after IO cessation in patients receiving no further treatment.~Patients will be centrally registered at the ELCWP headquarter (Institut Jules Bordet, Brussels, Belgium).
Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC.~The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.